Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028 [Seeking Alpha]
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Seeking Alpha
Kenneth Galbraith, Chairman, CEO, Acting CFO & President, opened by highlighting the Phase III HERIZON-GEA-01 trial results: "Zanidatamab in combination with chemotherapy with or without a checkpoint inhibitor demonstrated a median PFS exceeding one year with a Quick Insights FDA approval and potential milestone payments up to $1.5 billion could significantly boost Zymeworks' valuation and support expanded shareholder returns and strategic acquisitions. The note structures only 30% of royalties, preserving most cash flows and provides funds for share buybacks, acquisitions, and R&D, extending the cash runway beyond 2028. Operating expenses are expected to drop 20%, which can improve profitability, but analysts note the risk that reduced spending may impact the pace of R&D progress. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]Yahoo! Finance
- Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingGlobeNewswire
- Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
ZYME
Earnings
- 3/2/26 - Miss
ZYME
Sec Filings
- 3/2/26 - Form S-8
- 3/2/26 - Form 8-K
- 3/2/26 - Form 10-K
- ZYME's page on the SEC website